EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Real‐World Study of EGFR ‐ TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR ‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study

Kei Sonehara iD, Kazunari Tateishi iD, Kiyotaka Yoh, Kazuhiro Usui, Yukio Hosomi, Kazuma Kishi, Go Naka, Kageaki Watanabe, Shu Tamano, Kohei Uemura, Hideo Kunitoh

Thoracic Cancer · 2025-01 · 16 (2)

DOI: 10.1111/1759-7714.15507 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thoracic Cancer, online erschienen am 07.12.2024. Verfasst von Kei Sonehara und 10 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Acrylamides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

First‐line osimertinib is widely used to treat patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancers (NSCLC). In clinical practice, rechallenge therapy with another EGFR‐tyrosine kinase inhibitor (TKI) is often performed after first‐line TKI discontinuation owing to resistance or toxicity; however, the efficacy and toxicity of EGFR‐TKI rechallenge after first‐line osimertinib have not been adequately investigated. This study aimed to examine the efficacy and safety of EGFR‐TKI rechallenge with another TKI.

Methods

This multicenter prospective observational study enrolled patients with EGFR‐mutated NSCLC who received first‐line osimertinib and another EGFR‐TKI as second‐ or third‐line treatment between September 2018 and August 2020.

Results

Fifty‐three patients received rechallenge with another EGFR‐TKI in the second‐line ( n = 38, 71.7%) or third‐line ( n = 15, 28.3%) setting. The primary reason for first‐line osimertinib discontinuation was toxicity in 32 (60.4%, 17 patients with pneumonitis) and disease progression in 20 (37.7%) patients. The most common rechallenge EGFR‐TKI was afatinib ( n = 24, 45.3%), followed by gefitinib ( n = 16, 30.2%) and erlotinib ( n = 8, 15.1%). The real‐world time to treatment failure (rwTTF) was 7.3 months. The rwTTF for the toxicity discontinuation and progressive disease discontinuation groups was 9.3 months and 5.1 months, respectively, (HR 1.61, p = 0.119). EGFR‐TKI rechallenge was discontinued due to toxicity in nine patients (17.0%), but no patient developed pneumonitis.

Conclusion

EGFR‐TKI rechallenge with another TKI is well tolerated in patients with EGFR‐mutated NSCLC. Thus, it may be a useful treatment option after first‐line osimertinib failure, especially after osimertinib discontinuation due to toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAcrylamidesAniline CompoundsMutationHumansMaleFemaleAgedMiddle AgedErbB ReceptorsProspective StudiesAged, 80 and overAdultIndolesPyrimidines

Stichwörter der Autor:innen

epidermal growth factor receptornon‐small cell lung cancerosimertinibrechallengetyrosine kinase inhibitor

Substanzen

osimertinibProtein Kinase InhibitorsAcrylamidesEGFR protein, humanErbB ReceptorsAniline CompoundsIndolesPyrimidines

Autor:innen und Institutionen

  • First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Respiratory Medicine, NTT Medical Center Tokyo, Shinagawa, Tokyo, Japan.
  • Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan.
  • Department of Respiratory Medicine, Toho University Omori Medical Center, Ota, Tokyo, Japan.
  • Department of Respiratory Medicine, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.

ORCID-Profile: Kei Sonehara, Kazunari Tateishi

Förderung

  • AstraZeneca

Zitieren

APA

Sonehara, K., Tateishi, K., Yoh, K., Usui, K., Hosomi, Y., Kishi, K., Naka, G., Watanabe, K., Tamano, S., Uemura, K., & Kunitoh, H. (2025). Real‐World Study of EGFR ‐ TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR ‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study. Thoracic Cancer, 16(2). https://doi.org/10.1111/1759-7714.15507

Vancouver

Sonehara K, Tateishi K, Yoh K, Usui K, Hosomi Y, Kishi K, et al. Real‐World Study of EGFR ‐ TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR ‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study. Thoracic Cancer. 2025;16(2). doi:10.1111/1759-7714.15507

BibTeX
@article{Sonehara2025,
  author = {Sonehara, Kei and Tateishi, Kazunari and Yoh, Kiyotaka and Usui, Kazuhiro and Hosomi, Yukio and Kishi, Kazuma and Naka, Go and Watanabe, Kageaki and Tamano, Shu and Uemura, Kohei and Kunitoh, Hideo},
  title = {Real‐World Study of EGFR ‐ TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR ‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study},
  journal = {Thoracic Cancer},
  year = {2025},
  volume = {16},
  number = {2},
  doi = {10.1111/1759-7714.15507}
}
Kostenlos starten →